Technical Analysis for TSVT - 2seventy bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Earnings Movers | Other | -5.75% | |
| Multiple of Ten Bearish | Other | -5.75% | |
| Wide Bands | Range Expansion | -5.75% | |
| Oversold Stochastic | Weakness | -5.75% | |
| Stochastic Buy Signal | Bullish | -3.21% | |
| Wide Bands | Range Expansion | -3.21% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 3% | about 9 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 10 hours ago |
| Possible Inside Day | about 11 hours ago |
| Gap Down Closed | about 15 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/21/2023
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc. operates independently of bluebird bio, Inc. as of November 4, 2021.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Life Sciences Gene Therapy Multiple Myeloma Breakthrough Therapy Chimeric Antigen Receptor T Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Life Sciences Gene Therapy Multiple Myeloma Breakthrough Therapy Chimeric Antigen Receptor T Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 19.33 |
| 52 Week Low | 8.44 |
| Average Volume | 855,214 |
| 200-Day Moving Average | 13.53 |
| 50-Day Moving Average | 11.85 |
| 20-Day Moving Average | 11.02 |
| 10-Day Moving Average | 10.05 |
| Average True Range | 0.71 |
| RSI | 32.43 |
| ADX | 23.95 |
| +DI | 12.47 |
| -DI | 27.05 |
| Chandelier Exit (Long, 3 ATRs) | 11.83 |
| Chandelier Exit (Short, 3 ATRs) | 11.47 |
| Upper Bollinger Bands | 13.64 |
| Lower Bollinger Band | 8.41 |
| Percent B (%b) | 0.18 |
| BandWidth | 47.41 |
| MACD Line | -0.75 |
| MACD Signal Line | -0.62 |
| MACD Histogram | -0.1346 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.23 | ||||
| Resistance 3 (R3) | 10.32 | 10.12 | 10.08 | ||
| Resistance 2 (R2) | 10.12 | 9.89 | 10.07 | 10.03 | |
| Resistance 1 (R1) | 9.73 | 9.76 | 9.63 | 9.64 | 9.98 |
| Pivot Point | 9.53 | 9.53 | 9.48 | 9.48 | 9.53 |
| Support 1 (S1) | 9.14 | 9.30 | 9.04 | 9.05 | 8.70 |
| Support 2 (S2) | 8.94 | 9.17 | 8.89 | 8.65 | |
| Support 3 (S3) | 8.55 | 8.94 | 8.60 | ||
| Support 4 (S4) | 8.46 |
